A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Evaluate the Efficacy and Safety of PF614 for the Treatment of Moderate to Severe Pain After Abdominoplasty
Latest Information Update: 24 Mar 2025
At a glance
- Drugs PF 614 (Primary) ; Oxycodone
- Indications Postoperative pain
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Ensysce Biosciences
Most Recent Events
- 10 Mar 2025 According to an Ensysce Biosciences media release, company is finalizing the selection of clinical sites and an experienced team to execute PF614 phase 3 trial to remain on track to submit PF614 New Drug Application in 2026.
- 10 Mar 2025 According to an Ensysce Biosciences media release, the company announced that they have received feedback from the FDA on PF614 phase 3 study design and company is now and are now taking steps to prepare for the expected start of enrollment of this clinical study in the second quarter of 2025.
- 24 Sep 2024 Status changed to not yet recruiting.